Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 9/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.42 |
| ▸ | PLD2 | O14939 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680395 | 0.84 | ITGB3 (0.47) | HDAC2ROCK2PYGLSYK | |
| SCHEMBL5677265 | 0.76 | ITGB3 (0.54) | HDAC2PYGLNHERF1PLD2PLD1 | |
| SCHEMBL5896783 | 0.76 | ITGB3 (0.58) | HDAC2KDM4EHSD17B10 | |
| SCHEMBL5889622 | 0.76 | ITGB3 (0.53) | HDAC2ROCK2PYGLNHERF1PLD2 | |
| SCHEMBL5889728 | 0.75 | HDAC2 (0.49) | HDAC2ROCK2PYGLNHERF1PLD2 | |
| SCHEMBL5889562 | 0.74 | HDAC2 (0.50) | HDAC2ROCK2PYGLNHERF1KDM4E | |
| SCHEMBL5889537 | 0.74 | KDM4E (0.51) | HDAC2NHERF1PLD2PLD1KDM4E | |
| SCHEMBL5889814 | 0.73 | HDAC2 (0.50) | HDAC2ROCK2NHERF1PLD2PLD1 | |
| SCHEMBL5889830 | 0.73 | KDM4E (0.57) | HDAC2NHERF1PLD2PLD1KDM4E | |
| SCHEMBL5889522 | 0.73 | KDM4E (0.53) | HDAC2ROCK2PYGLNHERF1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | HDAC2 750/4885ROCK2 4167/4885PYGL 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.